Product nameAnti-HNF-1B antibody [EPR6334(2)]
See all HNF-1B primary antibodies
DescriptionRabbit monoclonal [EPR6334(2)] to HNF-1B
Tested applicationsSuitable for: WBmore details
Unsuitable for: ICC,IHC-P or IP
Species reactivityReacts with: Mouse, Rat, Human
Synthetic peptide within Human HNF-1B aa 500-600. The exact sequence is proprietary.
- Human fetal kidney and Caco 2 lysates.
This product was previously labelled as HNF1 beta.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20°C. Stable for 12 months at -20°C.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 50% Glycerol, 49% PBS, 0.05% BSA
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab128912 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Detects a band of approximately 61 kDa (predicted molecular weight: 61 kDa).|
FunctionTranscription factor, probably binds to the inverted palindrome 5'-GTTAATNATTAAC-3'.
Involvement in diseaseDefects in HNF1B are the cause of renal cysts and diabetes syndrome (RCAD) [MIM:137920]; also called maturity-onset diabetes of the young type 5 (MODY5) or familial hypoplastic glomerulocystic kidney disease (GCKD). RCAD is an autosomal dominant disorder comprising non-diabetic renal disease resulting from abnormal renal development, and diabetes, which in some cases occurs earlier than age 25 years and is thus consistent with a diagnosis of maturity-onset diabetes of the young (MODY5). The renal disease is highly variable and includes renal cysts, glomerular tufts, aberrant nephrogenesis, primitive tubules, irregular collecting systems, oligomeganephronia, enlarged renal pelves, abnormal calyces, small kidney, single kidney, horseshoe kidney, and hyperuricemic nephropathy.
Defects in HNF1B may be rare genetic risk factor contributing to the development of non-insulin-dependent diabetes mellitus (NIDDM) [MIM:125853]. NIDDM is characterized by an autosomal dominant mode of inheritance, onset during adulthood and insulin resistance.
Defects in HNF1B may be a cause of susceptibility to prostate cancer hereditary type 11 (HPC11) [MIM:611955]. It is a condition associated with familial predisposition to cancer of the prostate. Most prostate cancers are adenocarcinomas that develop in the acini of the prostatic ducts. Other rare histopathologic types of prostate cancer that occur in approximately 5% of patients include small cell carcinoma, mucinous carcinoma, prostatic ductal carcinoma, transitional cell carcinoma, squamous cell carcinoma, basal cell carcinoma, adenoid cystic carcinoma (basaloid), signet-ring cell carcinoma and neuroendocrine carcinoma.
Sequence similaritiesBelongs to the HNF1 homeobox family.
Contains 1 homeobox DNA-binding domain.
- Information by UniProt
- FJHN antibody
- Hepatocyte nuclear factor 1 beta antibody
- Hepatocyte nuclear factor 1-beta antibody
ab128912 has been referenced in 1 publication.
- Liu Q et al. Disruption of mesoderm formation during cardiac differentiation due to developmental exposure to 13-cis-retinoic acid. Sci Rep 8:12960 (2018). PubMed: 30154523